Balance Sheet - Lyell Immunopharma, Inc. (LYEL)
$(Billion, Million)| Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | |
|---|---|---|---|---|---|---|---|
| Total cash and short-term investments | 247.22 | 370.53 | 546.22 | 640.15 | 614.79 | 612.62 | 436.05 |
| Other current assets | 13.72 | 9.07 | 8.46 | 11.14 | 11.49 | 4.93 | 4.21 |
| Total current assets | 260.94 | 379.59 | 554.69 | 651.30 | 626.29 | 617.55 | 440.26 |
| Total non-current assets | 79.11 | 111.27 | 195.34 | 286.27 | 501.12 | 290.73 | 115.37 |
| Total assets | 340.05 | 490.86 | 750.03 | 937.56 | 1,127.41 | 908.28 | 555.63 |
| Total current liabilities | 49.41 | 53.79 | 34.52 | 37.03 | 46.74 | 49.29 | 22.05 |
| Total non-current liabilities | 42.44 | 54.25 | 60.56 | 67.28 | 150.88 | 140.56 | 125.53 |
| Total liabilities | 91.85 | 108.04 | 95.08 | 104.31 | 197.62 | 189.84 | 147.58 |
| Total stockholders' equity | 248.20 | 382.82 | 654.95 | 833.25 | 929.79 | 718.44 | 408.06 |
| Common shares outstanding | 17 | 13 | 13 | 12 | 12 | 12 | 12 |
Show Quarterly Balance Sheet
Balance Sheet - Lyell Immunopharma, Inc. (LYEL)
$(Billion, Million)| Mar-26 | Dec-25 | Sep-25 | Jun-25 | Mar-25 | Dec-24 | Sep-24 | Jun-24 | Mar-24 | Dec-23 | Sep-23 | Jun-23 | Mar-23 | Dec-22 | Sep-22 | Jun-22 | Mar-22 | Dec-21 | Sep-21 | Jun-21 | Mar-21 | Dec-20 | Sep-20 | Jun-20 | Mar-20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total cash and short-term investments | 254.02 | 247.22 | 319.62 | 276.79 | 301.18 | 370.53 | 440.55 | 491.12 | 526.30 | 546.22 | 575.43 | 595.75 | 612.77 | 640.15 | 648.13 | 655.56 | 613.91 | 614.79 | 618.92 | 824.52 | 604.93 | 612.62 | 0.00 | 0.00 | 436.05 |
| Other current assets | 13.28 | 13.72 | 8.58 | 5.42 | 8.00 | 9.07 | 9.50 | 8.71 | 7.87 | 8.46 | 11.42 | 10.66 | 11.63 | 11.14 | 11.61 | 11.21 | 11.79 | 11.49 | 12.23 | 10.32 | 4.80 | 4.93 | |||
| Total current assets | 267.30 | 260.94 | 328.20 | 282.21 | 309.18 | 379.59 | 450.05 | 499.82 | 534.16 | 554.69 | 586.85 | 606.41 | 624.40 | 651.30 | 659.75 | 666.78 | 625.71 | 626.29 | 631.15 | 834.84 | 609.74 | 617.55 | 436.05 | ||
| Total non-current assets | 83.32 | 79.11 | 79.76 | 103.24 | 120.62 | 111.27 | 169.17 | 154.32 | 160.06 | 195.34 | 208.14 | 228.94 | 256.05 | 286.27 | 317.52 | 354.90 | 446.40 | 501.12 | 567.19 | 395.03 | 267.45 | 290.73 | -436.05 | ||
| Total assets | 350.63 | 340.05 | 407.97 | 385.45 | 429.80 | 490.86 | 619.22 | 654.14 | 694.22 | 750.03 | 794.99 | 835.35 | 880.45 | 937.56 | 977.27 | 1,021.67 | 1,072.10 | 1,127.41 | 1,198.33 | 1,229.87 | 877.19 | 908.28 | |||
| Total current liabilities | 36.95 | 49.41 | 31.88 | 36.90 | 41.29 | 53.79 | 33.51 | 30.88 | 32.35 | 34.52 | 35.06 | 34.39 | 30.80 | 37.03 | 51.22 | 50.29 | 41.06 | 46.74 | 59.28 | 63.66 | 56.81 | 49.29 | |||
| Total non-current liabilities | 40.01 | 42.44 | 46.97 | 49.63 | 51.99 | 54.25 | 55.01 | 56.76 | 58.71 | 60.56 | 62.35 | 64.11 | 65.83 | 67.28 | 106.03 | 103.34 | 149.80 | 150.88 | 152.58 | 144.25 | 143.46 | 140.56 | |||
| Total liabilities | 76.96 | 91.85 | 78.84 | 86.53 | 93.28 | 108.04 | 88.52 | 87.64 | 91.06 | 95.08 | 97.42 | 98.50 | 96.62 | 104.31 | 157.24 | 153.63 | 190.85 | 197.62 | 211.86 | 207.91 | 200.27 | 189.84 | |||
| Total stockholders' equity | 273.67 | 248.20 | 329.12 | 298.92 | 336.52 | 382.82 | 530.70 | 566.50 | 603.16 | 654.95 | 697.57 | 736.86 | 783.83 | 833.25 | 820.03 | 868.04 | 881.25 | 929.79 | 986.47 | 1,021.96 | 676.92 | 718.44 | 408.06 | ||
| Common shares outstanding | 22 | 17 | 18 | 15 | 15 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |